Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia

Leukemia and Lymphoma

Volumn 56, Issue 1, 2015, Pages 85-91

  Liu, Xiao ^a   Wang, Dao Feng ^a   Fang, Yi ^a   Ye, Wen Feng ^a   Liu, Shu ^a   Lou, Ning ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Diagnosis; Febrile neutropenia; Infection; Non Hodgkin lymphoma; Procalcitonin; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITONIN; PROCALCITONIN; PROTEIN PRECURSOR;

ADOLESCENT; ADULT; AGED; BLOOD; CANCER STAGING; COMORBIDITY; COMPLICATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LYMPHOMA, NON-HODGKIN; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITONIN; COMORBIDITY; FEBRILE NEUTROPENIA; FEMALE; HUMANS; INFECTION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922389657     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.911864     Document Type: Article

References (43)

1. Zelenetz AD, Wierda WG, Abramson JS, et al. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw 2013;11:257-272; quiz 273.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069-2076.
4. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e56-e93.
5. Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 2011;26:220-252.
6. Reinhart K, Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 2011;27:253-263.
7. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-237.
8. Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med 2013;28:285-291.
9. Jullienne A, Segond N, Calmettes C, et al. Biosynthesis of human calcitonin: evidence for a prohormone. Biochem Biophys Res Commun 1980;95:932-937.
10. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inf ammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36:941-952.
11. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79:1605-1608.
12. LeMoullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984; 167: 93-97.
13. Russwurm S, Wiederhold M, Oberhofer M, et al. Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med 1999;37:789-797.
14. Hitoglou-Hatzi S, Hatzistilianou M, Gougoustamou D, et al. Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia. Clin Exp Med 2005;5:60-65.
15. Robinson JO, Lamoth F, Bally F, et al. Monitoring procalcitonin in febrile neutropenia:what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One 2011;6:e18886.
16. Jimeno A, Garcia-Velasco A, Del Val O, et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 2004;100:2462-2469.
17. Kim DY, Lee YS, Ahn S, et al. The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer Res Treat 2011; 43: 176-180.
18. Reitman AJ, Pisk RM, Gates JV, et al. Serial procalcitonin levels to detect bacteremia in febrile neutropenia. Clin Pediatr (Phila) 2012;51:1175-1183.
19. Svaldi M, Hirber J, Lanthaler AI, et al. Procalcitonin-reduced sensitivity and specif city in heavily leucopenic and immunosuppressed patients. Br J Haematol 2001;115:53-57.
20. Hatzistilianou M, Rekliti A, Athanassiadou F, et al. Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin Infect Dis 1998;27:914-5.
21. Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med 2013;28:285-291.
22. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2012;10:1412-1445.
23. Young L. Gram-negative sepsis. In: Mandell G, Douglas R, Bennet J, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone; 1990. pp 611-636.
24. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Ef ect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607.
25. Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013;21:1487-1495.
26. Prkno A, Wacker C, Brunkhorst FM, et al. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock-a systematic review and meta-analysis. Crit Care 2013;17:R291.
27. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions:past, present and future. BMC Med 2011;9:107.
28. Neuenschwander LC, Bittencourt H, Ribeiro AF, et al. Plasma levels of procalcitonin and eight additional inf ammatory molecules in febrile neutropenic patients. Clinics (Sao Paulo) 2011; 66: 1699-1705.
29. Miedema KG, de Bont ES, Elferink RF, et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 2011;19:1593-1600.
30. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-1332.
31. Schuetz P, Christ-Crain M, Wolbers M, et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections:A prospective, multicenter, randomized controlled trial. BMC Health Serv Res 2007; 7: 102.
32. Tang J, Long W, Yan L, et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma:A randomized controlled trial. BMC Infect Dis 2013;13:596.
33. Ahn S, YS Lee. Predictive factors for poor prognosis febrile neutropenia. Curr Opin Oncol 2012;24:376-380.
34. Lin SG, Hou TY, Huang DH, et al. Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and Neutropenia-a systemic review and meta-analysis. Pediatr Infect Dis J 2012;31:e182-e188.
35. Fu Y, Jiang H, Li LX, et al. Application value of procalcitonin and immune inf ammatory factors for prediction of bacteriemia in patients with hematologic malignancy combined with febrile neutropenia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013;21:1296-1300.
36. Delevaux I, Andre M, Colombier M, et al. Can procalcitonin measurement help in dif erentiating between bacterial infection and other kinds of infammatory processes? Ann Rheum Dis 2003;62: 337-340.
37. Lin SG, Hou TY, Huang DH, et al. Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and Neutropenia-a systemic review and meta-analysis. Pediatr Infect Dis J 2012;31:e182-e188.
38. Jedd R, Ghedira H, Ben Amor R, et al. Risk factorsofseptic shock in patients with hematologic malignancies and Pseudomonas infections. Hematology 2011;16:160-165.
39. Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012;40:43-49.
40. Nylen ES, Snider RH Jr, Thompson KA, et al. Pneumonitis-associated hyperprocalcitonemia. Am J Med Sci 1996;312:12-18.
41. Kherad O, Kaiser L, Bridevaux PO. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest 2010;138: 896-904.
42. Ammori BJ, Becker KL, Kite P, et al. Calcitonin precursors: early markers of gut barrier dysfunction in patients with acute pancreatitis. Pancreas 2003;27:239-243.
43. Magnotti LJ, Deitch EA. Burns, bacterial translocation, gut barrier function, and failure. Burn Care Rehabil 2005; 26: 383-391.